Dr. Lapuerta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
350 Carter Road
Princeton, NJ 08540Phone+1 609-466-5590- Is this information wrong?
Education & Training
- Harvard Medical SchoolClass of 1989
Certifications & Licensure
- CA State Medical License 1992 - Present
- NJ State Medical License 1996 - 2025
- NC State Medical License 1989 - 1991
Clinical Trials
- Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) Start of enrollment: 2007 Dec 01
- Pharmacodynamics of CGT 2168 Compared With Plavix® Start of enrollment: 2007 Nov 01
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Start of enrollment: 2010 Jun 15
Publications & Presentations
PubMed
- 12 citationsCost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.Vijay N. Joish, F. Frech, Pablo Lapuerta> ;Journal of Medical Economics. 2018 Feb 1
- 7 citationsBudgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan PerspectiveVijay N. Joish, Feride Frech, Pablo Lapuerta> ;Clinical Therapeutics. 2017 Dec 1
- 261 citationsEffects of Sotagliflozin Added to Insulin in Patients with Type 1 DiabetesSatish K. Garg, Robert R. Henry, Phillip Banks, John B. Buse, Melanie J. Davies, Gregory R. Fulcher, Paolo Pozzilli, Diane Gesty‐Palmer, Pablo Lapuerta, Rafael Simó, T...> ;The New England Journal of Medicine. 2017 Sep 13
- Join now to see all
Journal Articles
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Darren K Mcguire, Jeffrey M Testani, Pablo Lapuerta, Bertram Pitt, The New England Journal of Medicine
Press Mentions
- Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes CareJune 25th, 2018
- Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes CareJune 23rd, 2018
- Sotagliflozin (Zynquista): A Novel SGLT MedicationJune 16th, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: